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Endogenous mediators of growth 
B Y  N I G E L  L O V E R I D G E ,  C O L I N  F A R Q U H A R S O N  
A N D  B E N  A .  A .  S C H E V E N *  
Bone Growth mid Metaholirin Unit, Rowti  Reseurch Instititte. B~icksburn, Aberdeen AH2 9SN 
Growth comprises three separate componcnts; whole-body growth, tissue turnover and 
repair, and last, the response to external stimuli. Whole-body growth can be divided into 
changes associated with muscle, skin, viscera and skeleton. Because of our interest in 
bone metabolism the present review will concentratc on the processes associated with 
skeletal growth, turnover, and response to external stimuli. Although some of the factors 
which will be discussed are specific to bone the majority affect other body tissues. 
There are too many endogenous mediators of growth to list in a review such as this. 
Basically such mediators can be divided into two groups (Table 1), those which have a 
systemic action such as growth hormonc (GH) and those which act locally such as the 
transforming growth factors (TGF). Of those systemic factors, some such as GH have a 
general effect on a number of tissues. However, there are also systemic factors such as 
gonadotropins and ACTH which have trophic actions on particular target organs. 
Endogenous mediators of growth are varied as well as numerous. For instance. calcium 
can be considcred a growth mediator for the parathyroid gland as prolonged hypo- 
calcaemia results in a hypertrophy of the parathyroid gland. 
Bone growth and metabolism rely on the action of a number of factors affecting the 
proliferation and differentiation of the major bone cell types and modulating their 
activity. The skeleton serves a structural role, but it  is also responsible for maintaining 
normocalcaemia. These two functions may occasionally bc contradictory but the primary 
role is the maintenance of serum Ca and at times of Ca stress (e.g. pregnancy and 
lactation) this occurs at the expense of skeletal integrity. Therefore, skeletal growth and 
metabolism are governed by two series of factors; those which control skeletal growth 
(e.g. G H  and insulin-likc growth factor-1 (IGF-I)) and the calciotropic hormoncs 
(parathyroid hormone (PTH), calcitonin and 1,2.5-dihydroxycholecalciferol 
(1 ,25(OH)2D3)). It is becoming apparent that there is some overlap between these two 
systems as PTH, which at low levels is considered to be anabolic to the skeleton (Parsons 
et al. 1975), has recently been shown to increase the production of IGF-1 in bone cells 
(Canalis et a/. 1989; Linkhart & Mohan, 1989). 
The control of bone growth and metabolism is dependent on the activity and 
interactions of particular cell types. Thesc include the growth plate chondrocytes which 
are primarily responsible for longitudinal growth. The two cell types which are 
responsible for the turnover and repair of the skeleton are the osteoblasts which form 
bone and osteoclasts which resorb bone. This remodelling process is also important in 
intramembranous (skull growth) and endochondral bone formation during bone devel- 
opment and growth. The osteocyte, which is an osteoblast embedded in the matrix, is 
probably responsible for sensing the changes in mechanical demand (Pead et al. 1988). 
* Present addrcss: Acadernisch Ziekenhuis Utrecht. Post Box 85500. 3508 G A  Utrecht. Thc Netherlands. 
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Table 1. Some examples of the various types of endogenous mediutors of growth 
Systemic 
(a) General Growth hormone (GH) 
Insulin-like growth factors (IGF) 
Epidermal growth factor 
Thyroid hormones 
Insulin 
Thyroid-stimulating hormone 
Adrenocorticotrophin 
Calcium 
Insulin-like growth factors (IGF) 
Transforming growth factors (TGF) 
Platelet-derived growth factor 
Epidermal growth factor 
Osteoclast growth factor (OGF) 
Interlcukins 
(b) Organ specific Gonadotropins 
Local 
LOUGITUDINAL BONE G R O W T H  
The characteristic histological features of the long bones are developmentally regulated. 
At birth the columnar structure of the epiphyseal growth plate is incompletely formed. 
As a laminar organization of chondrocytes develops in the distal direction (Sissons, 1961) 
there is a uniformly distributed cell layer consisting of cells which rarely divide (Kember, 
1978). which is termed the germinal layer. During longitudinal growth these cells 
differentiate and enter the proliferative layer where the cells multiply before maturing 
into hypertrophic chondrocytes. These cells produce the cartilaginous matrix which 
subsequently becomes calcified before being resorbed and replaced by osteoblast- 
mediated bone formation (Isaksson et al. 1987). Thus, longitudinal growth results from 
the increased production of cells and their subsequent expansion. 
Post-natal longitudinal bone growth is primarily dependent on GH. but while effects of 
G H  are easily recognized, the site and cellular mechanisms behind these effects are 
unclear. Salmon & Daughaday (1957) postulated that response to GH was mediated 
through the hepatic production of somatomedins, now termed insulin-like growth factors 
(IGF). This is based on the fact that addition of GH to explanted cartilage fragments 
produces little effect on metabolism. However, addition of serum stimulated a number o f  
cellular functions associated with proliferation and differentiation. Serum from hypo- 
physectomized animals had a lesser effect but subsequent G H  therapy resulted in a 
serum with normal growth-promoting activities. The structure of both IGF has been 
elucidated (Rinderknecht & Humbel, 1978~l.h) and the genes encoding these f. cictors 
characterized (Jansen et al. 1983. 1985). 
However, Schoenle et al. (1982) infused high doses of purified IGF-1 into hypophysec- 
tomized rats but could only induce a slight increase in bone growth which was of a similar 
magnitude to that induced by GH alone. Similarly, in a study using recombinant IGF-1. 
high doses had t o  be used to induce bone growth, while GH was more effective at a 
fiftyfold lower dosc (Skottner et af. 1987). I t  is now apparent that while administration of 
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large doses of IGF-1 significantly increases body-weight, it produces only small effects on 
longitudinal bone growth. 
To examine the possibility that GH might have a direct cffect on the growth plate, 
Isaksson and colleagues (Isaksson et al. 1982: lsgaard et al. 1986; Nilsson et al. 1987) 
infused low concentrations of GH (50 ng/d) directly into the growth plate or into the 
knee joint and showed that it stimulated longitudinal growth compared with the 
contralateral limb. IGF-1 was also capable of stimulating epiphyscal cartilage width but a 
combination of thc two growth promoters produced no additional increase in bone 
growth. Other groups have confirmed much of this work (Russell & Spencer, 1985; 
Schlectcr ef al. 1986). 
These studies have been supportcd by the findings that many tissues produce IGF-1 
(D'Ercole et af. 1984) and has led to the development of an alternative concept of GH 
action whcreby GH has a direct effect on peripheral tissues which in turn mediate the 
effect by the local production of IGF-1 (Underwood et al. 1986). Many o f  the 
organ-specific growth mediators outlined in Table 1 have been shown to stimulate the 
local production of IGF-1 and IGF-1 may in turn potentiate the response to those growth 
mediators (for review, see Holly & Wass. 1989). One of the important questions for 
future research is whether the direct or indirect actions of GH on peripheral tissues are 
physiological and what is the relative contribution of each pathway to the final cffect. 
B I N D I N G  P R O T E I N S  
Both GH and IGF are either found free or complexed to binding proteins within the 
circulation. Human plasma is known to contain at least two binding proteins (>lo0 K 
and 80-85 K) for growth hormone each with varying degrees of affinity for human GH 
(Baumann et al. 1986; Herington et al. 1986). The high affinity peak (80-8s K) is 
responsible for 80-90% of the complexed GH (Baumann el al. 1989). Under physio- 
logical conditions approximatcly 50% and 29% of the circulating 22 K and 20 K human 
G H  respectively are in a complexed form (Baumann et al. 1988). At GH concentrations 
grcater than about 20 ng/ml thc complexed fraction declines in a concentration 
dependent manner due to partial saturation of the binding protein (Baumann et al. 
1988). 
The concentrations of both binding proteins vary considerably from subject to subject 
in health and disease but are grossly maintained within the normal rangc in a number of 
diverse conditions which are known to result in abnormal GH levels such as acute 
infection, liver cirrhosis. acromegaly. uraemia (Baumann et al. 1989). The levels of 
binding protein were, however, significantly lower in neonates but reached the adult 
levels by 1 year of age (Baumann et al. 1989). Limited evidence exists that thc two 
binding proteins are differentially regulated with the larger binding protein (> 100 K) 
having sex hormone dependency but not thc high-affinity binding protein (80-85 K). 
More than 98% of plasma IGF-1 and IGF-2 is bound to a 150 K complex whose 
concentration is GH dependent (Baxter & Martin, 1986). Acidification results in an 
acid-stable subunit of 50 K with a binding sitc with equal high affinity for either IGF-I or 
IGF-2 (Martin & Baxter: 1986). 
A group of smaller binding proteins (25-43 K) are also present in serum and one of 
these (26 K) is found in amniotic fluid (Povoa el al. 1984). The serum levels of this 
protein are low in acromegaly and raised in hypopituitarism so it is believed to be 
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inversely related to G H  (Drop et al. 1984). Injection of GH to GH-deficient patients 
resulted in a fall in the level of binding protein (Busby cf al. 1988), although it has been 
reported that the levels rise during the nocturnal increase in G H  secretion (Baxtcr & 
Colwcll, 1087). Studies on nutritional influences on this protein have shown that its 
concentration falls after a meal (Baxter & Colwell, 1987; Busby et al. 1988) and rises 
during overnight fasting (Busby et nl. 1988) and during the infusion of glucose and insulin 
(Sukkari et al. 1988). 
As the IGF- and GH-binding proteins have only recently been characterized the role 
of such binding proteins in thc expression of the biological activity of these growth 
promoters is as yet unclear. One function that has been attributed t o  them is to protect 
GH (Baumann et ul. 1987) and IGF (Cohen & Nissley, 1976) from degradation and 
prolonging their biological half-life by restricting their access to degradation sites. A 
number of other functions have speculatively been attributed to thc GH-binding protein. 
These include inhibition of GH action by interference with GH-receptor binding, 
enhancement of G H  action by acting as a cofactor for receptor binding or acting as a 
circulating hormone reservoir during periods o f  fluctuations in G H  secretion (Baumann 
et uf. 1987). Similarly, inhibition (Drop et ul. 1979; Zapf et al. 1979: Knauer 8: Smith, 
1980) or enhancement (Clemmons et af. 1986; Elgin et al. 1987) of the activity of IGF-I 
has been attributed to the low-molecular-weight IGF-binding proteins. The 150 K 
IGF-binding protein is considered due to its very long half-life (Hodgkinson ef af. 1987) 
to constitute an IGF storage compartment. 
The presence of these binding proteins has undoubtedly important implications in the 
mctabolism. distribution and physiological activity of G H  and the IGFs but these 
processes are as yet unclear and warrant further research. 
LOCAL. T U R N O V E R  AND R E P A I R  
The activity of osteoblasts and osteoclasts is closely coupled (Rodan & Martin, 1981) 
which results in skeletal turnover without accretion or loss. Both the activity and the 
proliferation and differentiation of bone cells appear to be under the control of a number 
of growth factors. The bone matrix itself is a storehouse for a plethora of factors which 
can induce bone formation. In thc 1960s, Marshall Urist (1965) showed that devitalized 
bone was capable of inducing cndochondral bone formation. Several groups have 
pursued this line of research and have purified a number of growth factors (Reddi & 
Anderson, 1976). 
In  addition to these bone spccitic growth factors there are othcr growth factors which 
have a more general activity and arc also found within the bone matrix. These include 
IGF-2 (Mohan et al. 1988), fibroblast growth factor (Hauschka et af. 1986) which is 
mitogenic for mesoderm- and neuroectoderm-derived cclls (Gospodarowicz et al. 1987) 
and TGF-P (Sporn et ul. 1987). 
Work in our laboratory is concerned with two aspects of the control of bone cell 
activity. First the development of novel techniques which enable the in sitri measurement 
of the biochemistry of bone cells (Bradbeer et al. 1988; Loveridge & Farquharson, 1989), 
and second the purification of a factor relcascd from osteoblasts which stimulates the 
proliferation and differentiation of osteoclasts (Dickson & Scheven, 1983; Scheven et af. 
1989). This factor affects the number of osteoclasts but not the activity of existing 
osteoclasts and has been termed osteoclast growth factor (OGF). 
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TGF-P is produced by osteoblasts in response to calciotropic hormones (Pfeilschifter 
& Mundy, 1987) and inhibits bone resorption induced by other factors (Pfeilschifter et al. 
1988). although in some systems it stimulates bone resorption (Tashjian et al. 1985). 
TGF-P is produced as a latent precursor molecule which is then cleaved t o  release the 
biologically active TGF-P (Sporn et al. 1987). a process of which the osteoclast is capable 
(Oreffo et al. 1989). In some but not all in vitro assays TGF-P stimulates markers of bone 
formation such as osteoblastic alkaline phosphatase (EC 3.1.3.1) activity (Pfcilschiftcr 
ef al. 1987). Thus, it has been suggested that TGF-P acts as an anabolic coupling factor 
by stimulating formation and inhibiting rcsorption. In our laboratory, however, while 
TGF-P inhibits osteoclastic activity it also inhibits osteoblastic activity (Loveridge & 
Farquharson, 1989), although the latter action is about 100 times less sensitive. 
R E S P O N S E  TO E X T E R N A L  S T I M U L I  
The last aspect of growth which we will discuss is the response to external stimuli. In the 
case of bone it is obvious that external stimuli such as dietary deficiencies of vitamin D, 
changes in the availability of Ca or increased demand for Ca result in alterations in the 
Ca homeostatic mechanisms with a consequent loss of skcletal material. Similarly 
metabolic diseases such as diabetes can result in significant bone loss (Hui et al. 1985). 
What is less well characterized is the response to mechanical stress. 
It is well known that the capacity of bone to remodel itself is influenced by the degrcc 
of mechanical loading. For instance, prolonged bed rest results in disuse ostcoporosis 
(Asher, 1947; Krolner & Toft, 1983). Furthermore, short periods of mechanical stress in 
which the magnitude and distributior. of the dynamic strains within the bone are different 
from those to which it is normally accustomed (Lanyon, 1984) result in profound changes 
in remodelling activity. 
What is not clear at present is the mechanism of response to loading, although recent 
evidence suggests a possible role for the osteocyte (Pead et al. 1988). 
S U M M A R Y  
In the present review it is not possible to discuss thc cffccts of the numerous endogcnous 
mediators of growth. What we have attempted to do is to indicate the areas of 
controversy and the need for further rcscarch. In our view, four main questions arise. 
First, what are the relative contributions of the direct and indirect effects of GH? Indeed. 
if GH can produce all its effects by local production of IGF, is the original somatomedin 
hypothesis still tenable'? Second, how is the biological activity of the 1GF modified by the 
presence of binding proteins? Because of the role of binding proteins in modulating IGF 
bioactivity, care must be taken when interpreting results from immunoassays for IGF 
because this will only represent the concentration of IGF not the level of biological 
activity, a situation which is analogous to that which pertains with certain polypeptide 
hormones (for review, see Robertson et al. 1987). Third, how are the activitics of the 
osteoblast and osteoclast coupled so that in the mature adult, bone formation and bone 
resorption are roughly equivalent? Understanding of this process will undoubtedly 
involve the elucidation of the roles arid interactions between a number of locally acting 
growth factors and systemic hormones and will lead to the understanding of certain 
metabolic bone diseases such as osteoporosis. Last, how is the response to local stimuli 
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such as mechanical stress transduced? This is again probably dependent on the activity of 
local growth factors but may also involve changes in the interactions between bone cells 
and their underlying matrix components (Skerry et al. 1988). 
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